A groundbreaking clinical trial has revealed that adding enzalutamide to standard hormone therapy can cut the risk of death by more than 40% in men whose prostate cancer returns after surgery or radiation. Credit: Shutterstock Men whose prostate cancer returns after surgery or radiation therapy may soon benefit from a powerful new treatment that has been shown in clinical trials to reduce the risk of death by more than 40%. Researchers tested a therapy that combines enzalutamide, an existing